Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Sims

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumChris Conklin, Stefan Radonjic, David Scott, et al.
JAMA Neurology|September 12, 2022
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical TrialSergey Shcherbinin, Cynthia D Evans, Ming Lu, et al.
Head & Neck|April 9, 2019
Vagal schwannomas of the head and neck: A comprehensive review and a novel approach to preserving vocal cord innervation and functionMykayla L Sandler, John R Sims, Catherine Sinclair, et al.
Head & Neck|July 26, 2020
Oral squamous carcinoma: Aggressive tumor pattern of invasion predicts direct mandible invasionLauren E Yue, Kayvon F Sharif, John R Sims, et al.
The Journal of Prevention of Alzheimer'S Disease|May 27, 2026
Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analysesFrank Jessen, Grazia Dell'Agnello, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 4, 2025
Donanemab immunogenicity in participants with early symptomatic Alzheimer's diseaseGarrett R Mullins, Paul Ardayfio, Ivelina Gueorguieva, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 20, 2025
TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's diseaseStephen Salloway, Andrew Pain, Elly Lee, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumChris Conklin, Stefan Radonjic, David Scott, et al.
JAMA Neurology|September 12, 2022
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical TrialSergey Shcherbinin, Cynthia D Evans, Ming Lu, et al.
Head & Neck|April 9, 2019
Vagal schwannomas of the head and neck: A comprehensive review and a novel approach to preserving vocal cord innervation and functionMykayla L Sandler, John R Sims, Catherine Sinclair, et al.
Head & Neck|July 26, 2020
Oral squamous carcinoma: Aggressive tumor pattern of invasion predicts direct mandible invasionLauren E Yue, Kayvon F Sharif, John R Sims, et al.
The Journal of Prevention of Alzheimer'S Disease|May 27, 2026
Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analysesFrank Jessen, Grazia Dell'Agnello, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 4, 2025
Donanemab immunogenicity in participants with early symptomatic Alzheimer's diseaseGarrett R Mullins, Paul Ardayfio, Ivelina Gueorguieva, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 20, 2025
TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's diseaseStephen Salloway, Andrew Pain, Elly Lee, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Pageof 10